Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RT...
| Autors principals: | , , , , , , |
|---|---|
| Format: | Journal article |
| Publicat: |
Oxford University Press
2017
|
| _version_ | 1826281549750861824 |
|---|---|
| author | Feagan, B Bhayat, F Khalid, J Palo, W Blake, A Shetzline, M Travis, S |
| author_facet | Feagan, B Bhayat, F Khalid, J Palo, W Blake, A Shetzline, M Travis, S |
| author_sort | Feagan, B |
| collection | OXFORD |
| description | Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting. |
| first_indexed | 2024-03-07T00:30:28Z |
| format | Journal article |
| id | oxford-uuid:7f9c9703-df1b-4787-ba58-212e164a8303 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:30:28Z |
| publishDate | 2017 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:7f9c9703-df1b-4787-ba58-212e164a83032022-03-26T21:18:00ZIncidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experienceJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f9c9703-df1b-4787-ba58-212e164a8303Symplectic Elements at OxfordOxford University Press2017Feagan, BBhayat, FKhalid, JPalo, WBlake, AShetzline, MTravis, SVedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting. |
| spellingShingle | Feagan, B Bhayat, F Khalid, J Palo, W Blake, A Shetzline, M Travis, S Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience |
| title | Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience |
| title_full | Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience |
| title_fullStr | Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience |
| title_full_unstemmed | Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience |
| title_short | Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience |
| title_sort | incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease clinical trial experience |
| work_keys_str_mv | AT feaganb incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience AT bhayatf incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience AT khalidj incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience AT palow incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience AT blakea incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience AT shetzlinem incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience AT traviss incidenceofpneumoniaandotherrespiratorytractinfectionswithvedolizumabtreatmentforinflammatoryboweldiseaseclinicaltrialexperience |